Kleo, Green Cross collaborate on COVID-19 NK combination therapy

By The Science Advisory Board staff writers

Kleo Pharmaceuticals is joining forces with Green Cross LabCell (GCLC) of South Korea to advance testing of natural killer (NK) cell therapies as a potential treatment for COVID-19 patients.

Kleo had received approval from the U.S. Food and Drug Administration (FDA) earlier this year to proceed with an antibody recruiting molecule (ARM)-NK cell combination therapy clinical trial for treatment of newly diagnosed multiple myeloma patients. The ARM in that trial targets the CD38 cell surface protein and uses autologous cytokine-induced memory-like NK cells to kill tumor cells, according to the company.

Meanwhile, GCLC's allogeneic NK cells are in late-stage clinical development in immuno-oncology applications and are projected to advance into the clinic for COVID-19 in the second half of this year, according to Kleo.

Kleo's ARM technology platform can develop fully synthetic bifunctional molecules that redirect a patient's own antibodies for therapeutic effect. The ARM has multiple proposed mechanisms of action in the context of a COVID-19 therapeutic, according to the company.

For example, it acts as a neutralizing antibody to block direct binding on the virus to human cells and also utilizes immune effector cells to eliminate viral particles and infected cells. What's more, the ARM can produce a long-term vaccination effect by activating and expanding immune memory cells, Kleo said.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?